Medical insurance reimbursement price of lorlatinib/lorlatinib in 2025

Lorlatinib is a third-generation ALK/ROS1 targeted inhibitor developed by Pfizer. It is mainly used to treat patients with ALK-positive or ROS1-positive non-small cell lung cancer (NSCLC). This drug can penetrate the blood-brain barrier and effectively control brain metastases. It is one of the important upgraded drugs in current ALK targeted therapy. With the advancement of precision medicine policies, lorlatinib has been officially launched in China and has been included in the National Medical Insurance Category B Catalog, allowing more lung cancer patients to receive treatment at a more reasonable cost.

According to current public information, the common specifications of the domestic original drug lorlatinib tablets are25 mg 90 tablets and 100 mg 30 tablets. The price per box is about RMB 20,000. However, due to the inclusion of medical insurance reimbursement, the actual out-of-pocket amount has dropped significantly. The medical insurance reimbursement ratio in different regions may be between 70% and 90%, and some cities can even further reduce the amount.

After medical insurance reimbursement, the patient burden of lorlatinib was significantly reduced. Compared with the cost of medication, which was often tens of thousands of yuan before it was included in medical insurance, this adjustment has greatly improved drug accessibility and compliance. It is worth mentioning that in some provinces, lorlatinib has been included in the reimbursement list of local special diseases, so that patients with advanced non-small cell lung cancer can receive continuous financial support for long-term treatment. In addition, some domestic pharmaceutical companies are also accelerating the research and development of generic drugs. Once approved for marketing, the overall price will be further reduced.

Overall, the medical insurance access of lorlatinib represents another breakthrough in China's policy in the field of high-end targeted drugs, allowing patients to enjoy internationally synchronized treatment options at a lower cost. As medical insurance negotiations continue to be optimized and the price reduction mechanism for imported drugs is improved, the market accessibility and user population of lorlatinib will further expand in the future. This will not only promote the development of targeted lung cancer treatment in China, but also provide new opportunities for the popularization of precision medicine.

References：https://www.lorbrena.com/